T cell activity in successful treatment of chronic urticaria with omalizumab

Clinical and Molecular Allergy

Volumn 9, Issue , 2011, Pages

  Sánchez Machín, Inmaculada ^a   Iglesias Souto, Javier ^a   Franco, Andrés ^b   Barrios, Yvelise ^b   Gonzalez, Ruperto ^a   Matheu, Víctor ^a,c  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLOSPORIN; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB;

ADULT; ANGIONEUROTIC EDEMA; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CASE REPORT; CD4+ T LYMPHOCYTE; CHRONIC URTICARIA; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HUMAN; LOW DRUG DOSE; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

EID: 79960694270     PISSN: None     EISSN: 14767961     Source Type: Journal    
DOI: 10.1186/1476-7961-9-11     Document Type: Note

References (12)

1. Saavedra MC, Sur S. Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clin Mol Allergy 2011, 9(1):2.. 10.1186/1476-7961-9-2, 3031269, 21247438.
2. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007, 99(2):190-193. 10.1016/S1081-1206(10)60644-8, 17718108.
3. Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008, 63(2):247-249. 10.1111/j.1398-9995.2007.01591.x, 18186820.
4. Matheu V, Franco A, Perez E, Hernandez M, Barrios Y. Omalizumab for drug allergy. J Allergy Clin Immunol 2007, 120(6):1471-1472. author reply 1472-1473.
5. Magerl M, Staubach P, Altrichter S, Ardelean E, Krause K, Metz M, Weller K, Maurer M. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol 2010, 126(3):665-666. 10.1016/j.jaci.2010.05.047, 20673981.
6. Vestergaard C, Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm Venereol 2010, 90(4):443-444. 10.2340/00015555-0884, 20574627.
7. Iemoli E, Piconi S, Fusi A, Borgonovo L, Borelli M, Trabattoni D. Immunological effects of omalizumab in chronic urticaria: a case report. J Investig Allergol Clin Immunol 2010, 20(3):252-254.
8. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003, 112(6):1147-1154. 10.1016/j.jaci.2003.10.003, 14657874.
9. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008, 122(3):569-573. 10.1016/j.jaci.2008.07.006, 18774392.
10. Noga O, Hanf G, Kunkel G, Kleine-Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol 2008, 146(1):66-70. 10.1159/000112504, 18087163.
11. Manga K, Serban G, Schwartz J, Slotky R, Patel N, Fan J, Bai X, Chari A, Savage D, Suciu-Foca N, et al. Increased adenosine triphosphate production by peripheral blood CD4+ cells in patients with hematologic malignancies treated with stem cell mobilization agents. Hum Immunol 2010, 71(7):652-658. 10.1016/j.humimm.2010.03.011, 20381567.
12. Matheu V, Perez E, Gonzalez R, Franco A, García-Robaina J, Barrios Y. T cell activation after Omalizumab for insulin allergy. J Allergy Clin Immunol 2008, 121(2, pt1):s38.